Swiss National Bank Purchases 2,100 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Swiss National Bank grew its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Rating) by 1.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 119,060 shares of the biopharmaceutical company’s stock after purchasing an additional 2,100 shares during the quarter. Swiss National Bank’s holdings in Agios Pharmaceuticals were worth $3,343,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Signaturefd LLC raised its stake in shares of Agios Pharmaceuticals by 92.5% during the third quarter. Signaturefd LLC now owns 1,003 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 482 shares in the last quarter. Point72 Hong Kong Ltd bought a new position in shares of Agios Pharmaceuticals during the 2nd quarter valued at $39,000. Lazard Asset Management LLC raised its position in Agios Pharmaceuticals by 37.9% in the 1st quarter. Lazard Asset Management LLC now owns 2,930 shares of the biopharmaceutical company’s stock worth $84,000 after purchasing an additional 805 shares during the period. HBK Sorce Advisory LLC bought a new stake in Agios Pharmaceuticals in the third quarter worth $169,000. Finally, Inspire Investing LLC purchased a new stake in Agios Pharmaceuticals during the third quarter valued at about $206,000.

Wall Street Analyst Weigh In

Several research analysts have recently commented on AGIO shares. StockNews.com initiated coverage on Agios Pharmaceuticals in a report on Thursday. They issued a “sell” rating on the stock. SVB Securities lowered their price objective on Agios Pharmaceuticals from $37.00 to $34.00 in a research report on Friday, May 5th. Piper Sandler began coverage on shares of Agios Pharmaceuticals in a report on Friday, February 3rd. They issued an “overweight” rating and a $41.00 target price on the stock. Finally, Piper Jaffray Companies started coverage on shares of Agios Pharmaceuticals in a research note on Friday, February 3rd. They issued an “overweight” rating and a $41.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $37.00.

Agios Pharmaceuticals Price Performance

AGIO opened at $26.10 on Monday. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of -6.57 and a beta of 0.96. Agios Pharmaceuticals, Inc. has a one year low of $16.75 and a one year high of $34.76. The business has a 50 day simple moving average of $23.22 and a two-hundred day simple moving average of $26.39.

Agios Pharmaceuticals (NASDAQ:AGIO – Get Rating) last announced its quarterly earnings results on Thursday, February 23rd. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of ($1.59) by $2.26. The company had revenue of $4.31 million during the quarter, compared to analyst estimates of $4.42 million. Agios Pharmaceuticals had a negative return on equity of 20.23% and a negative net margin of 1,146.58%. As a group, sell-side analysts expect that Agios Pharmaceuticals, Inc. will post -6.16 EPS for the current fiscal year.

Insider Activity

In other Agios Pharmaceuticals news, Director David P. Schenkein sold 20,000 shares of the firm’s stock in a transaction dated Monday, March 13th. The shares were sold at an average price of $22.49, for a total value of $449,800.00. Following the completion of the sale, the director now directly owns 117,879 shares in the company, valued at $2,651,098.71. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director David P. Schenkein sold 20,000 shares of the company’s stock in a transaction on Monday, March 13th. The stock was sold at an average price of $22.49, for a total value of $449,800.00. Following the sale, the director now directly owns 117,879 shares of the company’s stock, valued at $2,651,098.71. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director David P. Schenkein sold 16,363 shares of the firm’s stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $22.85, for a total value of $373,894.55. Following the transaction, the director now directly owns 117,879 shares of the company’s stock, valued at approximately $2,693,535.15. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 56,867 shares of company stock valued at $1,278,937. Corporate insiders own 4.48% of the company’s stock.

About Agios Pharmaceuticals

(Get Rating)

Agios Pharmaceuticals, Inc is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.